// App-Quantinova.ai

629 : Neoadjuvant nivolumab combined with CCR2/5 inhibitor or anti-IL-8 antibody in non-small cell lung cancer and hepatocellular carcinoma

Researchers

Presenter

  • Nicholas Venturini

Principal Investigators

  • Maria Casanova-Acebes

  • John Mandeli

  • Deborah Doroshow

  • Natalie Lucas

  • Kathy Wu

  • Olivia Hapanowicz

  • Paula King

  • Pauline Hamon

  • Jessica Le Berichel

  • Diane Del Valle

  • Clotilde Hennequin

  • Seunghee Kim-Schulze

  • Sacha Gnjatic

  • Miriam Merad

  • Zhen Zhao

  • Stephen Ward

  • Maria Isabel Fiel

  • Mary Beasley

  • Edward Kim

  • Kirema Garcia-Reyes

  • Udit Chaddha

  • Timothy Harkin

  • David Yankelevitz

  • Ganesh Gunasekaran

  • Parissa Tabrizian

  • Myron Schwartz

  • Andrew Kaufman

  • Daniel Nicastri

  • Andrew Wolf

  • Raja Flores

Medical Centers

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Centro Nacional de Investigaciones Oncologicas, Madrid, Spain

Locations

  • United States

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

  • Liver cancer

  • Small cell lung cancer

  • Lung Cancer

  • Solid malignancies

Biomarkers

  • C-C Motif Chemokine Receptor 2

Drug/Treatment

  • BMS-813160

  • HuMax IL8

  • Nivolumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • II

Study Id's

  • NCT04123379

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved